Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Filed Pursuant to Rule 424(b)(3)
Registration No.: 333-210567

Prospectus Supplement

(To Prospectus dated April 13, 2016)

 

A NWORTH M ORTGAGE A SSET C ORPORATION

Common Stock

6.25% Series B Cumulative Convertible Preferred Stock

7.625% Series C Cumulative Redeemable Preferred Stock

 

 

This prospectus supplement relates to sales of an aggregate of 4,367 shares of our Series C Cumulative Redeemable Preferred Stock (which we refer to as our “Series C Preferred Stock”) made in at-the-market transactions during the three month period ended September 30, 2016. MLV & Co. LLC (which we refer to as “MLV”) acted as our agent with respect to these sales pursuant to an At Market Issuance Sales Agreement, dated March 3, 2015, among us, Anworth Management LLC, and MLV, as described in the accompanying prospectus, as supplemented. In connection with these sales, we paid commissions to MLV as follows:

 

Gross proceeds to us from sales of Series C Preferred Stock		$	109,320
Commission to MLV		$	1,093
Net proceeds, before expenses, to us		$	108,227

You should read carefully this prospectus supplement and the accompanying prospectus, dated April 13, 2016, and each supplement thereto before you invest. These documents contain information you should consider when making your investment decision.

Our common stock trades on the New York Stock Exchange under the symbol “ANH.” On October 4, 2016, the last reported sales price of our common stock was $4.78 per share. Our Series B Cumulative Convertible Preferred Stock (which we refer to as our “Series B Preferred Stock”) trades on the New York Stock Exchange under the symbol “ANHPrB.” On October 4, 2016, the last reported sales price of our Series B Preferred Stock was $24.46 per share. Our Series C Preferred Stock trades on the New York Stock Exchange under the symbol “ANHPrC.” On October 4, 2016, the last reported sales price of our Series C Preferred Stock was $25.00 per share.

 

 

Investing in our capital stock involves a high degree of risk. See “Risk Factors” beginning on page 8 of the accompanying prospectus, as supplemented, to read about factors you should consider before buying shares of our common stock, Series B Preferred Stock, or Series C Preferred Stock.

 

 

Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

 

 

The date of this Prospectus Supplement is October 5, 2016